Greg Freiherr, Industry Consultant

Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Blog | Greg Freiherr, Industry Consultant | Radiology Imaging| June 15, 2016

How the Trump Candidacy Might Energize Men’s Healthcare

Trump, PSA, prostate cancer

Image courtesy of Pixabay.

Personalized medical care conjures an image of exactness. Precision. Its realization was once believed attainable through sequencing the human genome. But when that didn’t happen, the concept was redefined as healthcare tailored to the individual.

Finding disease at its earliest stages through screening is a big part of it. The widespread use of mammography and testing for the gene associated with breast cancer have gone a long way in this regard for women’s health. But how to achieve similar gains for men?

Donald Trump’s candidacy might provide the answer.

Trump may not have actually drawn more people to the GOP, as he has claimed over and over. But the presumptive Republican nominee unquestionably has brought voters into the political process earlier than ever before.

Might the segment of the electorate energized by Trump be harnessed to propel the technological development and ultimately widespread use of a screening test for prostate cancer? A major segment of Trump supporters — middle-aged men — is at risk of developing this disease.

Politics can be the fuel for technological development. Lobbyists can promote funding for research, technological development and the reimbursement of procedures. Lobbying may be especially effective when supported by grassroots efforts.

Nothing so incentivizes people like fear, a fact proven by Trump. And there is plenty of reason to be afraid of prostate cancer. According to the U.S. government, prostate cancer is the most common non-skin cancer and the second leading cause of cancer-related death in men in the United States. It was estimated that, in 2014, 233,000 men in the U.S. would be diagnosed with prostate cancer. Nearly 29,500 would die of the disease.

 

The “Unprotected”

As February drew to a close, Peggy Noonan of the Wall Street Journal wrestled with the incomprehensibility of Trump as the enunciated the idea of “protection” as an explanation GOP nominee and what had propelled him to that point. She opined that the protected in America — the elite who have money, live in safe neighborhoods, have functioning families, and whose kids go to good schools — make public policy. The unprotected, who have none of these and instead lived in the rougher world created for them, had begun to push back — powerfully, she wrote.

According to a survey from RAND Corporation, voters who agreed with the statement “people like me don't have any say about what the government does” were 86.5 percent more likely to prefer Trump.

Judging from Trump’s success, the unprotected want change. After the presidential election, will they acquiesce? Or might their wants be channeled to other causes? Might they be mobilized to support the development and use of a screening tool for prostate cancer? What will be needed for that to happen?

 

Better Testing Needed

One thing is for sure. The current blood test built on measuring prostate-specific antigen (PSA) needs to be replaced. Although the likelihood of prostate cancer increases with the rising levels of PSA, abnormal values have been associated with benign conditions, according to Harvard Medical School. PSA testing is so woefully inadequate that many advisory groups recommend against routine screening for prostate cancer. (A large American study found that screening for prostate cancer did not reduce the chance of dying from the disease.1)

Blood, tissue and urine samples may contain better biomarkers than PSA. Ongoing research is looking into those possibilities. And there are a number of imaging possibilities, including PET, SPECT and MRI.

Where might this technological potential take us? Probably nowhere, unless driven politically. To be successful, a campaign to develop and utilize a screening test for prostate cancer must resonate with a substantial block of voters.

The segment of the electorate energized by the Trump candidacy might be that block.

 

Additional reading:

1Andriole GL, Crawford ED, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J National Cancer Institute 2012; 104:125.

Editor's note: This is the third blog in a four-part series on screening. The first blog, “Screening: How New Looks at Old Modalities Might Turn Imaging Upside Down,” can be found here. The second blog, “Why Developing Multiple Screening Technologies is a Must,” can be found here.

Related Content

Novel PET Agent Could Help Guide Therapy for Brain Diseases

Rat brain 11C‐Me‐NB1 PET images (0‐60 min) superimposed on an MRI template. Credit: SD Krämer et al., ETH Zurich, Zurich, Switzerland

News | PET Imaging | April 10, 2018
Researchers have developed a new imaging agent that could help guide and assess treatments for people with various...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
What is the cost of interrupting a radiologist?
News | Clinical Study | March 20, 2018
March 20, 2018 – A first of its kind study...
Siemens Healthineers Launches New Partners for Digital Ecosystem at HIMSS 2018
News | PACS Accessories | March 12, 2018
At the 2018 Healthcare Information and Management Systems Society (HIMSS) Annual Conference and Exhibition, March 5-9...
Alternative Technique Can Improve Brain Imaging for Restless Children
News | Pediatric Imaging | March 08, 2018
March 8, 2018 – Children often find it difficult to remain still for...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain.

This figure shows two different brains that are aligned to a common template space for comparison. The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain. CREDIT: Zachariah Reagh

News | Nuclear Imaging | March 08, 2018
As we get older, it's not uncommon to experience "senior moments," in which we forget where we parked our car or call...
Sponsored Content | Case Study | Radiology Imaging | March 06, 2018
As one of the largest Catholic, not-for-profit healthcare systems in the United States, St. Louis-based SSM Health has...
Imaging Plays Key Role in Evaluating Injuries at Olympics
News | Orthopedic Imaging | February 28, 2018
The Olympic Games give elite athletes a chance at athletic triumph, but also carry a risk of injury. When injuries...
Overlay Init